Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059

Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials

Andrews, J. S., Desai, U., Kirson, N. Y., Zichlin, M. L., Ball, D. E., & Matthews, B. R. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.005 · Cited by 338

Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non‐orphan, Non‐oncology Drugs in the European Union and United States from 2012−2016

Morant, A. V., Jagalski, V., & Vestergaard, H. T. (2019) · Clinical and Translational Science · doi:10.1111/cts.12617 · Cited by 22

A Bayesian perspective on Biogen's aducanumab trial

Temp, A. G. M., Ly, A., van Doorn, J. B., Wagenmakers, E., Tang, Y., Lutz, M. W., & Teipel, S. J. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12615 · Cited by 14

Exosomes in Age-Related Cognitive Decline: Mechanistic Insights and Improving Outcomes

Duggan, M. R., Lu, A., Foster, T. C., Wimmer, M. E., & Parikh, V. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.834775 · Cited by 15

Amyloid-beta Targeted Therapeutic Approaches for Alzheimer’s Disease: Long Road Ahead

Dai, Y., Lei, C., Zhang, Z., Qi, Y., Lao, K., & Gou, X. (2022) · Current Drug Targets · doi:10.2174/1389450123666220421124030 · Cited by 15

Enzyme–substrate interface targeting by imidazole‐based γ‐secretase modulators activates γ‐secretase and stabilizes its interaction with APP

Petit, D., Hitzenberger, M., Koch, M. K., Lismont, S., Zoltowska, K. M., Enzlein, T., Hopf, C., Zacharias, M., & Chávez‐Gutiérrez, L. (2022) · The EMBO Journal · doi:10.15252/embj.2022111084 · Cited by 12

Promoting Endogenous Neurogenesis as a Treatment for Alzheimer’s Disease

Zhang, Q., Liu, J., Chen, L., & Zhang, M. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03145-2 · Cited by 15

Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review

Dickson, S. P., Hennessey, S., Johnson, J. N., Knowlton, N., & Hendrix, S. B. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01238-1 · Cited by 14

Aducanumab delivery via focused ultrasound-induced transient blood–brain barrier opening in vivo

Jeong, J., Han, M., Jeon, S., Kim, Y., Choi, H. J., Choi, W., Kwon, K., Choi, J.-R., & Lee, E.-H. (2025) · Scientific Reports · doi:10.1038/s41598-025-02412-1 · Cited by 13

Network-Medicine-Guided Drug Repurposing for Alzheimer’s Disease: A Multi-Dimensional Systems Pharmacology Approach

Akgüller, Ö., Balcı, M. A., & Cioca, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010003 · Cited by 13

Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease

Hao, Y., Dong, M., Sun, Y., Duan, X., & Niu, W. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1147757 · Cited by 13

Profiling aducanumab as a treatment option for Alzheimer’s disease: an overview of efficacy, safety and tolerability

Thussu, S., Naidu, A., Manivannan, S., & Grossberg, G. T. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2402058 · Cited by 14

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

Cummings, J. L., Aisen, P. S. S., Lemere, C. A., Atri, A., Sabbagh, M. N., & Salloway, S. (2021) · Aktualności Neurologiczne · doi:10.15557/an.2021.0014 · Cited by 12

Advances in Neurorestoratology—Current status and future developments

Huang, H., Ramón‐Cueto, A., Masri, W. E., Moviglia, G. A., Saberi, H., Sharma, H. S., Otom, A. H., Chen, L., Siniscalco, D., & Sarnowska, A. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.04.003 · Cited by 12

Practice Effects in Mild Cognitive Impairment Increase Reversion Rates and Delay Detection of New Impairments

Sanderson‐Cimino, M. E., Elman, J. A., Tu, X. M., Gross, A. L., Panizzon, M. S., Gustavson, D. E., Bondi, M. W., Edmonds, E. C., Eppig, J. S., Franz, C. E., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.847315 · Cited by 13

Design, synthesis and structure-activity relationship studies of 3-phenylpyrazino[1,2-a]indol-1(2H)-ones as amyloid aggregation and cholinesterase inhibitors with antioxidant activity

Gujral, S. S., Shakeri, A., Hejazi, L., & Rao, P. P. N. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100075 · Cited by 12

Using Stems to Bear Fruit: Deciphering the Role of Alzheimer’s Disease Risk Loci in Human-Induced Pluripotent Stem Cell-Derived Microglia

Wickstead, E. S. (2023) · Biomedicines · doi:10.3390/biomedicines11082240 · Cited by 11

Recent advances in understanding Alzheimer’s Disease: diagnosis and management strategies

Marín, A., & Budson, A. E. (2023) · Faculty Reviews · doi:10.12703/r/12-24 · Cited by 12

Still grasping at straws: donanemab in Alzheimer’s disease

Doggrell, S. A. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1948010 · Cited by 12

The Anti-Aggregative Peptide KLVFF Mimics Aβ1-40 in the Modulation of Nicotinic Receptors: Implications for Peptide-Based Therapy

Trebesova, H., Olivero, G., Marchi, M., & Grilli, M. (2022) · Biomedicines · doi:10.3390/biomedicines10092231 · Cited by 10

Addition of inflammation-related biomarkers to the CAIDE model for risk prediction of all-cause dementia, Alzheimer’s disease and vascular dementia in a prospective study

Trares, K., Wiesenfarth, M., Stocker, H. R., Perna, L., Petrera, A., Hauck, S. M., Beyreuther, K. T., Brenner, H., & Schöttker, B. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00427-2 · Cited by 10

Cell-specific Nav1.6 knockdown reduced astrocyte-derived Aβ by reverse Na+-Ca2+ transporter-mediated autophagy in alzheimer-like mice

Wang, X., Wu, W., Yang, G., Yang, X., Ma, X., Zhu, D., Ahmad, K., Khan, K., Wang, Y., Sui, A., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.07.024 · Cited by 11

Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders

Lasheen, N. N., Allam, S., Elgarawany, A., Aswa, D. W., Mansour, R., & Farouk, Z. E. (2024) · The Journal of Physiological Sciences · doi:10.1186/s12576-024-00933-4 · Cited by 12

Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer’s

Song, T., Wang, Y., Silverglate, B., & Grossberg, G. T. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2357637 · Cited by 13

Alterations in Self-Aggregating Neuropeptides in Cerebrospinal Fluid of Patients with Parkinsonian Disorders

Zhu, S., Bäckström, D., Forsgren, L., & Trupp, M. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-213031 · Cited by 10

Small Molecules N-Phenylbenzofuran-2-carboxamide and N-Phenylbenzo[b]thiophene-2-carboxamide Promote Beta-Amyloid (Aβ42) Aggregation and Mitigate Neurotoxicity

Zhao, Y., & Rao, P. P. N. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00576 · Cited by 10

Cognitive Effect of Transcranial Direct Current Stimulation on Left Dorsolateral Prefrontal Cortex in Mild Alzheimer’s Disease: A Randomized, Double-Blind, Cross-Over Small-Scale Exploratory Study

Wang, C. S., Chen, P. S., Tsai, T.-Y., Hou, N.-T., Tang, C.-H., Chen, P., Huang, Y., & Cheng, K. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240002 · Cited by 9

Application of predictive models in boosting power of Alzheimer's disease clinical trials: A post hoc analysis of phase 3 solanezumab trials

Ezzati, A., Davatzikos, C. A., Wolk, D. A., Hall, C. B., Habeck, C. G., & Lipton, R. B. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12223 · Cited by 9

In vitro and in vivo biological evaluation of newly synthesized multi-target 20(R)-panaxadiol derivatives for treating Alzheimer's disease

Pang, L., Li, J., Liu, Z., Quan, Y., Sui, H., Jia, Y., Chen, F., Lee, J. J., Liu, P., Quan, Z., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114825 · Cited by 9

The effect of a digital health coaching and health education protocol on cognition in adults at-risk for Alzheimer’s

Campitelli, A., Gills, J. L., Jones, M. D., Paulson, S., Myers, J. R., Bryk, K. N., Madero, E. N., Glenn, J. M., Rodgers, C. H., Kempkes, J. A., et al. (2022) · GeroScience · doi:10.1007/s11357-022-00711-3 · Cited by 8

Novel Balance Mechanism Participates in Stem Cell Therapy to Alleviate Neuropathology and Cognitive Impairment in Animal Models with Alzheimer’s Disease

Qin, C., Li, Y., & Wang, K. (2021) · Cells · doi:10.3390/cells10102757 · Cited by 8

Communicating and Using Dementia Risk Evidence

Rosen, A. C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220722 · Cited by 9

DeepDrug: An Expert-led Domain-specific AI-Driven Drug-Repurposing Mechanism for Selecting the Lead Combination of Drugs for Alzheimer’s Disease

Li, V. O., Han, Y., Kaistha, T., Zhang, Q., Downey, J., Gozes, I., & Lam, J. C. (2024) · doi:10.1101/2024.07.06.24309990 · Cited by 8

Alzheimer's disease and the immune system: A comprehensive overview with a focus on B cells, humoral immunity, and immunotherapy

Afrakoti, L. G. M. P., Moghadam, S. D., & Hadinezhad, P. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251329188 · Cited by 12

Controversial Approval of New Drug to Treat Alzheimer's Disease

Aschenbrenner, D. S. (2021) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000794244.40800.99 · Cited by 7

Investigating the Impact of Sorghum on Tau Protein Phosphorylation and Mitochondrial Dysfunction Modulation in Alzheimer’s Disease: An In Vitro Study

Rezaee, N., Hone, E., Sohrabi, H. R., Adisa, A. R., Johnson, S. K., Gunzburg, S. T., Martins, R. N., & Fernando, W. M. A. D. B. (2025) · Nutrients · doi:10.3390/nu17030516 · Cited by 7

Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit

Frölich, L., & Hausner, L. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01222-w · Cited by 7

Aducanumab: una mirada dos años después de su aprobación

Jaimes, A. T., Camargo, L., & López, N. (2024) · Biomédica · doi:10.7705/biomedica.6967 · Cited by 7

FDA calls for investigation into industry influence during Alzheimer’s drug approval

Dyer, O. (2021) · BMJ · doi:10.1136/bmj.n1778 · Cited by 7

Probing the interactions between amyloidogenic proteins and bio-membranes

Ma, L., Li, X., Petersen, R. B., Peng, A., & Huang, K. (2023) · Biophysical Chemistry · doi:10.1016/j.bpc.2023.106984 · Cited by 7

Aduhelm: The Best Hope for Alzheimer’s Disease Patients or the Worst Decision the FDA Has Ever Made?

Kurkinen, M., & Tran, L. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215105 · Cited by 7

Impact of Helicobacter pylori eradication on age-specific risk of incident dementia in patients with peptic ulcer disease: a nationwide population-based cohort study

Kang, D. W., Lee, J.-W., Park, M. Y., Kim, S., Um, Y. H., Wang, S., Lee, C. U., & Lim, H. K. (2024) · GeroScience · doi:10.1007/s11357-024-01284-z · Cited by 6

‘Small benefits and a certain risk’: Media representations of novel treatments for Alzheimer's disease

Abeysinghe, S., Tao, Y., Kyei-Baffour, P. A., & Adrion, E. (2024) · Social Science & Medicine · doi:10.1016/j.socscimed.2024.117554 · Cited by 8

Association of Rheumatoid Arthritis With Progression of Cognitive Impairment and Risk of Mortality in People With Dementia

Mo, M., Eriksdotter, M., Ajeganova, S., Mitra, S., Ptacek, S. G., & Xu, H. (2025) · Neurology · doi:10.1212/wnl.0000000000213405 · Cited by 9

AI-Based Facial Emotion Analysis for Early and Differential Diagnosis of Dementia

Bergamasco, L., Coletta, A., Olmo, G., Cermelli, A., Rubino, E., & Rainero, I. (2025) · Bioengineering · doi:10.3390/bioengineering12101082 · Cited by 6

Prodromal Glutamatergic Modulation with Riluzole Impacts Glucose Homeostasis and Spatial Cognition in Alzheimer’s Disease Mice

Findley, C. A., McFadden, S., Cox, M. F., Sime, L. N., Peck, M. R., Quinn, K., Bartke, A., Hascup, K. N., & Hascup, E. R. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221245 · Cited by 6

Integrating in vitro disease models of the neurovascular unit into discovery and development of neurotherapeutics

Ding, Y., Shusta, E. V., & Palecek, S. P. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100341 · Cited by 6

Masitinib attenuates neuropathological changes in acrolein-induced sAD mouse model via NF-κB/NLRP3/Caspase-1 signaling pathway

Kang, J., Shen, Q., Zhang, Z., Liu, Y., Chen, Y., Ding, C., Wang, S., Wei, C., Ren, Y., Liang, Z., et al. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138300 · Cited by 6

Low-intensity pulsed ultrasound enhances microglial-mediated Aβ clearance and synaptic preservation in an APP transgenic mouse model of Alzheimer's disease

Su, W.-S., Wu, M.-T., Cheng, I. H.-J., & Yang, F. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115420 · Cited by 5

Development of a Low-Molecular-Weight Aβ42 Detection System Using a Enzyme-Linked Peptide Assay

Kim, S., Lee, E.-H., Kim, H., Kim, A.-R., Kim, Y.-E., Lee, J., Yoon, M., & Koh, S. (2021) · Biomolecules · doi:10.3390/biom11121818 · Cited by 5

Circadian rhythm disruption and retinal dysfunction: a bidirectional link in Alzheimer's disease?

Carrero, L., Antequera, D., Municio, C., & Carro, E. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.390962 · Cited by 5

Novel therapeutic approaches for targeting Alzheimer’s disease

Khodakiya, A., Chaudhary, S., Chaudhary, A., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00020-0 · Cited by 5

The Ups and Downs of Amyloid in Alzheimer's

Siemers, E., Aisen, P. S. S., & Carrillo, M. C. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.54 · Cited by 5

Out with the old, in with the new: Could plasma exchange be used to fill a therapeutic gap in neurology?

Spencer, J. I., Crane, M., Pisa, M., Waldman, A. D., & DeLuca, G. C. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120056 · Cited by 5

Aducanumab for Alzheimer’s disease: expediting approval and delaying science

Salinas, R. A. (2021) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2021-111765 · Cited by 5

Heterogeneous Treatment Effect Estimation using machine learning for Healthcare application: tutorial and benchmarkPreprint

Ling, Y., Upadhyaya, P., Chen, L., Jiang, X., & Kim, Y. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2109.12769 · Cited by 8

Rejection of Aducanumab (Aduhelm) by the Health Care Community

Bauchner, H., & Alexander, G. C. (2022) · Medical Care · doi:10.1097/mlr.0000000000001716 · Cited by 5

Utilizing MCID for evaluating clinical relevance of AD therapeutic interventions

Hamilton, J. L., Fuller, R. L. M., Modi, N., & Sampaio, C. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70138 · Cited by 4

Mitigation of CXCL10 secretion by metabolic disorder drugs in microglial-mediated neuroinflammation

Oliai, S. F., Shippy, D. C., & Ulland, T. K. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578364 · Cited by 4

Reimbursement recommendations before and after adoption of application fees by the Canadian Agency for Drugs and Technologies in Health: a cross-sectional study

Lexchin, J. (2024) · Journal of Pharmaceutical Health Services Research · doi:10.1093/jphsr/rmaf004 · Cited by 4

Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value

Cliff, E. R. S., & Kelkar, A. H. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3101 · Cited by 4

The effects of high plasma levels of Aβ1-42 on mononuclear macrophage in mouse models of Alzheimer’s disease

Li, C., Liu, K., Zhu, J., & Zhu, F. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00366-4 · Cited by 6

Making Health Care Smarter: The Role of Machine Learning Algorithms

Bisht, A., Dhiman, D., & Yamsani, N. (2023) · International Conference on Contemporary Computing and Informatics (IC3I) · doi:10.1109/ic3i59117.2023.10397900 · Cited by 4

The utility of recruitment incentives in early Alzheimer's disease trials

Ritchie, M., Witbracht, M. G., Russ, E., Sajjadi, S. A., Thai, G. T., Tam, S. P., Gillen, D. L., & Grill, J. D. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14143 · Cited by 4

Structural and Functional Determinants of ARIA-H Risk in Anti-Amyloid Monoclonal Antibodies: A Comparative Mechanistic Framework for Alzheimer's Immunotherapy Development

An, D., Zou, X., & Xu, Y. (2025) · Current Neuropharmacology · doi:10.2174/011570159x391766250806091602 · Cited by 3

Value‐based prices of emerging disease‐modifying therapies for Alzheimer's disease in 174 countries: a cost‐effectiveness and threshold analysis

Hoang, M. T., Kahn, J. G., Saha, S., & Trépel, D. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71308 · Cited by 3

Recombinant antibodies recognize conformation-dependent epitopes of the leucine zipper of misfolding-prone myocilin

Patterson-Orazem, A. C., Qerqez, A. N., Azouz, L. R., Thu, M., Hill, S. E., Ku, Y., Schildmeyer, L. A., Maynard, J. A., & Lieberman, R. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101067 · Cited by 3

Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer’s Disease Trials

Ritchie, M., Witbracht, M. G., Nuño, M. M., Hoang, D. K., Gillen, D. L., & Grill, J. D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220801 · Cited by 3

Automatic Detection of Cognitive Impairment Through Facial Emotion Analysis

Bergamasco, L., Lorenzo, F., Coletta, A., Olmo, G., Cermelli, A., Rubino, E., & Rainero, I. (2025) · Applied Sciences · doi:10.3390/app15169103 · Cited by 4

FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps

Rizk, J. G., & Lewin, J. C. (2022) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2022-111914 · Cited by 3

Active immunization: A novel therapeutic strategy for treating Alzheimer's disease

Mazahir, F. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178288 · Cited by 3

Elucidating the pharmacological mechanism of Yangming-Kaixin-Yizhi formula in inhibiting neuronal ferroptosis via Nrf2 in Alzheimer’s disease: a study combining network pharmacology, transcriptomics, and experimental validation

Xiong, R., Liu, P., Wang, L., Zhang, S., Liu, H., Rong, C., Kehriman, N., Wang, J., Wang, J., Lai, X., et al. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01814-y · Cited by 2

Recent advances towards BACE1 drug discovery and therapeutics design

Imran, S., Patel, M., Noroozifar, M., & Kerman, K. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md01095k · Cited by 4

A paradigm of the diagnosis and treatment for the whole process of Alzheimer’s disease

Shi, J., Du, Y., Wang, H., Zhang, N., Chen, W., Ni, J., Lu, X., Sun, Y., Wang, G., Liu, J., et al. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2672193 · Cited by 3

Influence on regulatory decisions for drugs with limited evidence

van Doorn-Khosrovani, S. B. V. W., & Olivier, T. (2026) · BMJ · doi:10.1136/bmj-2026-137466 · Cited by 2

Independent Advice on Drug Approvals: an Investigation of EMA Practices

Daval, C. J. R., Kesselheim, A. S., Sharpless, L. K., & Sarpatwari, A. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08495-8 · Cited by 2

Alzheimer’s Disease: Pathogenesis, Hypothesis and Management

Anjum, R. (2023) · Punjab University journal of zoology · doi:10.17582/journal.pujz/2023.38.2.229.236 · Cited by 2

Aducanumab Fails to Produce Efficacy Results Yet Obtains US Food and Drug Administration Approval

Angelo, M., & Ward, L. (2021) · Population Health Management · doi:10.1089/pop.2021.0189 · Cited by 2

Does the FDA‐approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?

Gleason, A. J., Ayton, S., & Bush, A. I. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51408 · Cited by 2

Combination Functional and Structural Imaging for the Diagnosis of Neurodegenerative Dementias – A Suggested Imaging Strategy

Duignan, J. A., Ryan, D. T., McNeill, G., & Killeen, R. P. (2021) · doi:10.47275/2332-4864-119 · Cited by 2

On Gaps of Clinical Diagnosis of Dementia Subtypes: A Study of Alzheimer’s Disease and Lewy Body DiseasePreprint

Wei, H., Masurkar, A. V., & Razavian, N. (2021) · medRxiv · doi:10.1101/2021.05.05.21256720 · Cited by 2

New IDEAS Amyloid Imaging 2021 Study: Running in Place with Ineffective Anti-Amyloid Treatments for Alzheimer’s Disease Patients

Barrio, J. R., Whitehouse, P. J., Alavi, A. A., & Høilund‐Carlsen, P. F. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210383 · Cited by 2

Graves disease is associated with increased risk of clinical Alzheimer’s disease: evidence from the Medicare system

Yashkin, A. P., Kolpakov, S. A., Ukraintseva, S. V., Yashin, A. I., & Akushevich, I. V. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00170-z · Cited by 1

Immunotherapy of Alzheimer’s Disease

Tondo, G., Marchi, F. D., Anselmi, M., & Comi, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_51 · Cited by 1

Cobalt complexes as modulators against amyloid-β aggregation

Yoo, J., Suh, J., Kim, G., Bernard, H., Tripier, R., Kim, D., Kim, M., & Lim, M. H. (2025) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2025.112972 · Cited by 1

Structural Assessment of Fibrillated Beta Amyloid to Reveal the Potential Epitopes for Alzheimer’s Disease

Hwang, H., Park, D., & Kim, J. (2026) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01982-1 · Cited by 1

Evolving Pharmacotherapies Involving Neuroimmune Crosstalk

Maurya, R., Ali, K., Soni, H., Mhatre, A., & Naqvi, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-5088-3_12 · Cited by 1

Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression

da Silva, A. M. P., de Deus, O., Cardoso, L. J. C., Ribeiro, F. V., Meldola, P. F., Menezes, I. R., Han, M. L., Quiroga, D. G., Almeida, K. J., Santos, D. H., et al. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2631536 · Cited by 1

A survey of the clinical pipeline in neuroscience

Brown, D. G., & Wobst, H. J. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128482 · Cited by 1

Converging multi-modality datasets to build efficient drug repositioning pipelines against Alzheimer’s disease and related dementias

Yin, Z., & Wong, S. T. C. (2022) · Medical Review · doi:10.1515/mr-2021-0017 · Cited by 1

Causal associations between neuroinflammation and Alzheimer's disease risk

Lin, K., & Yu, Y. (2022) · International Conference on Bioinformatics and Biomedical Science (ICBBS) · doi:10.1145/3571532.3571536 · Cited by 1

Exploring the effectiveness and safety profile of TAU protein antibodies as potential therapies for alzheimer's disease: a comprehensive review

Essa, M., Ahmed, N., Kakar, A., Akber, W., Barech, S., Farooq, A., & Mumtaz, T. (2024) · doi:10.32948/ajsep.2024.03.28 · Cited by 1

How Attribution Theory Helps to Explain Psychiatric Nosology

Garrett, M. D. (2024) · American Journal of Health Research · doi:10.11648/j.ajhr.20241204.13 · Cited by 1

A Drug Repositioning Approach Reveals Ergotamine May Be a Potential Drug for the Treatment of Alzheimer’s Disease

Wang, Q., Fu, M., Gao, L., Yuan, X., & Wang, J. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240235 · Cited by 1

Therapeutic promise of α-hederin in Alzheimer’s disease: Insights into inflammation, oxidative stress, and apoptosis modulation

Chettupalli, A. K., Gupta, N., Bukke, S. P. N., Singh, M. P., & Mandal, C. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118803 · Cited by 1

My head just exploded, now what? Aducanumab

Lundebjerg, N. E. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17350 · Cited by 1

Dementia Experts on Why the FDA Approval of Aducanumab for Alzheimer's Gets Mixed Grades

Talan, J. (2021) · Neurology Today · doi:10.1097/01.nt.0000767180.04997.ec · Cited by 1

Erstes kausal wirkendes Medikament gegen Alzheimer?

Häger, K. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01182-1 · Cited by 1

FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment

Ho, C., Lim, H. J., & Regier, D. A. (2022) · Current Oncology · doi:10.3390/curroncol29020036 · Cited by 1

An ultra-low dose of Δ9-tetrahydrocannabinol improves Alzheimer’s Disease-related cognitive deficitsPreprint

Nitzan, K., Ellenbogen, L., Beniamin, T., Sarne, Y., & Doron, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457252 · Cited by 1

AMDA Position Statement on Aducanumab

Watson, L. C., & Juman, R. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.07.024

Die Struktur des Cyclodecatriens Collinolacton, seine Biosynthese und semisynthetische Derivate: monopolare Spindeln und Schutz vor intrazellulärem oxidativem Stress

Schmid, J. C., Frey, K., Scheiner, M., Garzón, J. F. G., Stafforst, L., Fricke, J., Schuppe, M., Schiewe, H., Zeeck, A., Weber, T., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202106802

The Accelerated Approval of Aducanumab for Treatment of Patients With Alzheimer Disease

Steinbrook, R. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.4622 · Cited by 34

What the Aducanumab Approval Reveals About Alzheimer Disease Research

Manly, J. J., & Glymour, M. M. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3404 · Cited by 83

Aducanumab (Aduhelm) for Alzheimer's disease.

(2021) · PubMed

Approval of Aducanumab for Alzheimer Disease—The FDA’s Perspective

Dunn, B., Stein, P., & Cavazzoni, P. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.4607 · Cited by 246

Alzheimer’s disease: the controversial approval of Aducanumab

Tagliavini, F., Tiraboschi, P., & Federico, A. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05497-4 · Cited by 23